Key facts
- Prellis Biologics’s last known valuation is $110.1M (Nov 2023).
- It has raised $70.2M across 5 recorded rounds; the latest was Early Stage VC ($17.0M) in Jun 2022.
- Notable investors include Plug and Play Tech Center, SOSV, Khosla Ventures, IndieBio, True Ventures — 16 tracked in total.
- Prellis Biologics has filed 5 Form Ds with the SEC since 2017, most recently Jul 2022 ($17.0M sold to 19 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Prellis Biologics
Funding rounds
5 roundsAbout Prellis Biologics
Developer of a bioprinting technology designed to recreate and engineer human tissues in vitro. The company's technology precisely reproduces the human immune response through the creation of lymph node organoids and can exploit fully human immune responses for a variety of applications, including antibody discovery, immunogenicity assessment, and tumor-immune models, improving patients' lives by addressing challenges commonly faced in early-stage drug discovery and translational pharmacology.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2016
- Employees
- 50
- Website
- prellisbio.com/
- Ownership
- Privately Held (backing)
Prellis Biologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Prellis Biologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Prellis Biologics in its N-PORT filings yet. We sweep new filings monthly.